Neurosterix
CompanySwitzerland
Neurosterix develops one asset, in phase 1 (NTX-253 in schizophrenia). Mostly small molecule; based in Switzerland.
- 1
- Asset
- Furthest stage
- Phase 1
- 0
- Trials
- 1
- Signal
Pipeline
1Allosteric modulator for schizophrenia
Phase 1, Small molecule, schizophrenia
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Signals1
- Similar companies6